New studies offer insight into disease’s treatment, lingering symptoms

LEM Surgical announced that it received FDA 510(k) clearance for its Dynamis robotic surgical system for hard tissue surgery.

ENGLEWOOD, Colo., April 24, 2025 /PRNewswire/ — CIRCA Scientific is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the PeriCross™ Epicardial Access Kit (formerly Rook®), a purpose-built solution designed to enable controlled and efficient access to the pericardial space via a subxiphoid approach.

Indiana University School of Medicine scientists have developed a powerful new imaging technique to study bone marrow in mouse models. By overcoming key challenges unique to imaging this complex tissue, this advancement could support future drug development and therapies for conditions involving bone marrow, including cancers, autoimmune diseases and musculoskeletal disorders.

Researchers at the University of California San Diego School of Medicine have identified a potential new treatment, an investigational drug called lorundrostat, for individuals with uncontrolled or treatment-resistant hypertension, commonly known as high blood pressure.

Researchers have identified a key enzyme driving forms of Parkinson’s disease, and have shown how blocking it restores normal function in animal and cell models, offering a promising new drug target for the condition.

Innovative mesh aims to improve patient outcomes by naturally absorbing into the body post-surgery.

Designed to optimize bone regeneration, the new graft technology promises superior clinical outcomes in spinal and orthopedic procedures.

Innovative endovascular treatment for communicating hydrocephalus gains regulatory support for patients aged 12 and older.

DURHAM, N.C., April 23, 2025 /PRNewswire/ — Baebies has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Anti-Factor Xa test on the FINDER® platform —the first point-of-care heparin monitoring assay. Designed for patients receiving unfractionated or low molecular weight heparin, the test provides results in under 15 minutes from just 50 µL of whole blood. This designation recognizes the test’s potential to bring heparin monitoring closer to the patient, enabling faster and more effective dose management in critical care settings.